I used to think the ethical debate around IVF was mainly about access—who gets the technology and who doesn’t. But what’s unfolding with preimplantation genetic testing (PGT) is different. Personally, I think we’re crossing a more unsettling line: from using genetics to prevent severe disease, to using genetics as a kind of “future forecasting” tool for traits that are deeply shaped by life, not just DNA.
What makes this particularly fascinating—and frightening—is that the science is moving faster than the social imagination. The moment people can buy a prediction, even an imperfect one, society starts treating that prediction as destiny. And once that happens, the legal and ethical rules tend to arrive only after the market has already set the tone.
Beyond disease prevention
PGT began with a clear, morally legible purpose: identifying embryos likely to carry single-gene or serious inherited conditions, then selecting embryos to reduce harm. In my opinion, that narrow goal aligns with a widely shared intuition—prevent suffering, don’t manufacture perfection.
But the contemporary shift is toward polygenic scores, which attempt to estimate complex risk factors and traits using many small genetic signals at once. Personally, I think the hard part isn’t the existence of polygenic scores; it’s what people will do with them once they become commercially available and emotionally compelling.
Here’s a detail that I find especially interesting: polygenic predictions are probabilistic and often incomplete, because they can’t fully account for environment, upbringing, education, health behaviors, and countless unpredictable life events. What many people don't realize is that “linked to” is not the same as “determines,” and “higher risk” is not the same as “will happen.” That nuance matters ethically, because parents aren’t just receiving information—they’re making high-stakes decisions.
This raises a deeper question: when uncertainty becomes a product, who bears the cost of being wrong? If the outcome doesn’t match the prediction, the ethical burden can quietly shift from science to the child’s life.
The uncertainty people don’t want to hear
If you take a step back and think about it, the biggest moral risk might be psychological rather than biological. Personally, I think parents naturally want to reduce fear, and genetic testing offers a seductive feeling of control.
But the challenge is that complex traits—like cognitive abilities, susceptibility to common diseases, or even behavioral-related tendencies—emerge from a tug-of-war between genes and environment. Ishii’s core warning resonates with me: polygenic scores predict tendencies using genetic variants while largely ignoring how life will actually unfold.
What this really suggests is a kind of mismatch between statistical models and human expectations. People often treat a number like it’s a verdict, even when it’s more like a weather forecast with weak resolution. In my opinion, that misunderstanding is the ethical accelerant—once you believe the forecast, it reshapes parenting decisions, school choices, and even how the child is emotionally perceived.
One thing that immediately stands out is how easily “risk reduction” can morph into “trait optimization.” And when optimization becomes the aim, the emotional stakes rise: failure to meet expectations may feel like a moral disappointment.
A global patchwork of rules
The regulatory landscape is telling. Countries are not just disagreeing about science—they’re disagreeing about what kind of society they want to be.
In the United States, polygenic embryo screening has been available commercially since 2019, and surveys suggest many people are open to it, including for non-medical traits. Personally, I think commercialization is not neutral; it acts like an amplifier. When clinics market tests, the conversation shifts from “Should we?” to “Why not?”
Across parts of Europe, the approach is more cautious. Germany and Italy generally limit testing to preventing serious disease, while the UK currently does not permit polygenic scores for embryo selection. From my perspective, these limits reflect a societal instinct to protect reproductive decisions from turning into lifestyle branding.
And in many other places, unclear regulations create a vacuum where the market can move quickly. What many people don’t realize is that regulatory uncertainty doesn’t pause progress—it accelerates it by outsourcing judgment to providers. When rules are absent, ethics becomes ad hoc and uneven, depending on where a patient happens to live.
Eugenics—less as ideology, more as atmosphere
The word “eugenics” is heavy for a reason. Personally, I think the most dangerous thing about revived eugenic thinking isn’t only explicit authoritarian control—it can reappear in softer, consumer-friendly forms.
The ethical concerns raised around stigmatization and “children as products” feel especially relevant here. If people start selecting embryos based on predicted intelligence, appearance-related traits, or future disease risk, society may implicitly rank human lives before birth.
This is the part I can’t shake: even if today’s intent is protective or aspirational, outcomes can still produce hierarchies. A child who isn’t “as predicted” could face subtle stigma—“we tried,” “we expected,” “you didn’t deliver.”
Personally, I think the eugenics danger lies in the story people tell themselves. The story becomes: genetics is fate, and parents are entitled to shape fate. Historically, that mindset doesn’t stay contained; it spreads through institutions, media narratives, and eventually policy.
Autonomy, consent, and the child’s position
One overlooked ethical dimension is the child’s autonomy. A prediction made before birth can define how the child is treated afterward, even if the prediction was probabilistic.
I find this particularly interesting because it forces us to confront an uncomfortable reality: reproduction technology is often discussed in terms of parental choice, but the child’s experience comes later, with far less power to consent. If a child discovers they were selected based on a forecast they can’t verify or control, what does that do to their sense of self?
As Ishii notes, environmental influences and parental behavior matter enormously, and genetics doesn’t guarantee outcomes. Personally, I think that uncertainty should translate into humility in decision-making. Yet the technology tempts people into certainty, and certainty tempts people into overreach.
The deeper cultural trend: predictive life
Zoom out, and this isn’t just about embryos. This is part of a broader cultural shift toward predictive thinking: genetic risk dashboards, quantified self-tracking, algorithmic recommendations, and the belief that more data equals more control.
What this really suggests is that PGT-PS fits a larger pattern where people outsource moral responsibility to models. In my opinion, the temptation is to treat biology as an inventory system: label, score, filter.
The question then becomes: what happens when human life is treated as a set of probabilities? Personally, I think the risk is not only inequality in access, but inequality in dignity—some children being implicitly engineered for “better outcomes,” while others become the default exceptions.
Where cautious policy should land
I’m sympathetic to the idea that policymakers should adopt precautionary regulation while public understanding catches up. From my perspective, clear guidelines can prevent the worst abuses without halting legitimate medical use.
At minimum, I think regulators should insist on honest framing of uncertainty, strict limits on what can be tested for non-medical traits, and strong oversight of how clinics market these tools. Public education matters too, because if people hear “intelligence score” or “disease likelihood” without understanding statistical limits, the debate becomes emotionally unmanageable.
What many people don't realize is that good oversight isn’t just about preventing harm; it’s about shaping expectations so that families don’t build their hopes on fragile predictions.
A personal takeaway
Personally, I think the ethical alarm isn’t that genetics is being used—it’s that people are being sold a sense of certainty. When predictions about complex traits become part of reproductive choice, we aren’t only selecting embryos; we’re selecting narratives about what a “good life” should look like.
If you take a step back and think about it, this raises a provocative question: do we want parenthood to be a form of care under uncertainty, or a product built around optimization? I can’t pretend the answer is obvious, but I do believe the rules should move faster than the marketing.
Would you like me to write this article in a more journalistic tone (less personal) or keep the heavy first-person commentary style you requested?
